Skip to Main Content

Advertisement

Skip Nav Destination

Abstract PR11: Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents.

Mol Cancer Ther (2013) 12 (11_Supplement): PR11.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal